13 results about "Virus Binding" patented technology

The invention relates to a medical xenon recovery system based on multistage filtration and dynamic separation. The medical xenon recovery system comprises a pretreatment and microorganism inactivation module, a gas purification and separation module, a xenon circulation distribution module, an intelligent monitoring system and a dynamic pressure compensation mechanism. The invention further relates to a medical xenon recovery method based on multi-stage filtration and dynamic separation, bacteria are intercepted through the filter screen, viruses are intercepted through large particles, short-wave sterilization ultraviolet LED array irradiation is combined, double barriers of physical interception and ultraviolet inactivation are formed, the method is far superior to a traditional single filtration technology, the grade cleaning standard is met, and the medical xenon recovery method has the advantages of being simple in operation, low in cost and high in efficiency. The system thoroughly solves the biological potential safety hazard of lack of ultra-small virus interception and inactivation in the prior art, can efficiently inactivate respiratory pathogens, can effectively prevent microorganisms in exhaled air from circulating to patients or medical staff through a recovery system, is especially suitable for infectious surgery scenes, and remarkably reduces the risk of cross infection in hospitals.

The present disclosure is directed to antibodies binding to and neutralizing henipavirus and methods for use thereof. Thus, in accordance with the present disclosure, there is provided a method of detecting a henipavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and (b) detecting henipavirus in said sample by binding of said antibody or antibody fragment to a henipavirus antigen in said sample.

A kind of MOFs nano-enzyme and application in new coronavirus detection, it relates to biological detection method field, MOFs-based nano-enzyme has peroxidase-like effect, can catalyze color developing agent discoloration;After the specific protein CD147 is modified on the surface of nano-enzyme, using the specific binding of CD147 and the S protein overexpressed on the surface of new coronavirus, new coronavirus can be efficiently combined on the surface of nano-enzyme to inhibit the catalytic color development of nano-enzyme;Based on the principle, the quantitative and qualitative detection of new coronavirus can be realized by colorimetric method;The present application realizes the rapid, high-sensitivity and visual detection of new coronavirus by the inherent catalytic advantage of nano-enzyme and the specific recognition and binding capacity of CD147 to new coronavirus without additional labeling process, and can effectively identify new coronavirus infection.

The present invention relates to a bifunctional peptide comprising a virus-binding portion (2) and a mucin-binding portion (1) covalently linked to the virus-binding portion (2). The virus-binding portion is selected from peptides that bind to SARS-CoV-2, influenza A virus, influenza B virus, rhinovirus and other enteroviruses, human parainfluenza virus, and / or metapneuvirus. The mucin-binding portion is selected from lectins such as trefoil factor 3.

Provided herein is a DNA-based nanostructure at least a first plurality of virus-binding moieties, wherein each virus-binding moiety of the at least first plurality of virus-binding moiety is neuraminic acid or a derivative thereof. Also provided herein is a self-assembling DNA-based building block formed by a single-stranded DNA template strand and a set of oligonucleotides complementary to said single-stranded DNA template, wherein: each of the oligonucleotides is either complementary to one contiguous DNA sequence stretch or to at least two non-contiguous DNA sequence stretches on said single-stranded DNA template; and the self-assembling DNA-based building block comprises at least one first virus-binding moiety, wherein the first virus-binding moiety is neuraminic acid or a derivative thereof. Also provided herein is a DNA-based nanostructure wherein the DNA-based nanostructure comprises at least five self-assembling DNA-based building blocks; each of the self-assembling DNA-based building blocks is formed by a single-stranded DNA template strand and a set of oligonucleotides that are at least partially complementary to said single-stranded DNA template; and wherein each of the oligonucleotides is either complementary to one contiguous DNA sequence stretch or to at least two non-contiguous DNA sequence stretches on said single-stranded DNA template. Also provided herein are associated methods, uses, compositions, and kits.

This invention discloses a homogeneous polysaccharide from *Rhizoctonia solani* that exhibits antiviral activity against human cytomegalovirus in both the virus-cell binding stage and the post-virus invasion stage, along with its preparation method and applications. This polysaccharide is a homogeneous polysaccharide Ts1-1A extracted, isolated, and purified from the fruiting bodies of *Rhizoctonia solani*. *Rhizoctonia solani* homogeneous polysaccharide Ts1-1A is a novel heteropolymer containing partially branched chains, with its main chain consisting of →3)-α-Fuc p -(1→and→6)-α-Gal p -(1→ Composed in a 1:1 ratio, with T-α-Man branches p -(1→, connected to the 2nd and 3rd positions of the same Gal on the main chain, with an average of 2 branches replacing every 16 sugar residues in the main chain. During the viral attachment period, it can prevent the virus from adsorbing onto cell surface receptors by binding to the virus. At the same time, after entering the cell, it can inhibit viral replication through antioxidant effects, thereby exerting an antiviral effect.

Provided herein are compositions including a binding reagent for a Zika virus (ZIKV) epitope, pharmaceutical compositions including such binding reagents, and methods of detecting ZIKV binding antibodies and ZIKV neutralizing antibodies in patients.

Provided herein is a DNA-based nanostructure at least a first plurality of virus-binding moieties, wherein each virus-binding moiety of the at least first plurality of virus- binding moiety is a neuraminidase inhibitor. Also provided herein is a DNA-based nanostructure at least a first plurality of virus-binding moieties, wherein each virus- binding moiety of the at least first plurality of virus-binding moiety is a neuraminidase- binding moiety and / or a haemagglutinin-binding moiety. Also provided herein is a self- assembling DNA-based building block formed by a single-stranded DNA template strand and a set of oligonucleotides complementary to said single-stranded DNA template, wherein: each of the oligonucleotides is either complementary to one contiguous DNA sequence stretch or to at least two non-contiguous DNA sequence stretches on said single-stranded DNA template; and the self-assembling DNA-based building block comprises at least one first virus-binding moiety, wherein the first virus- binding moiety is a neuraminidase-binding moiety and / or a haemagglutinin-binding moiety. Also provided herein is a DNA-based nanostructure wherein the DNA-based nanostructure comprises at least five self-assembling DNA-based building blocks; each of the self-assembling DNA-based building blocks is formed by a single-stranded DNA template strand and a set of oligonucleotides that are at least partially complementary to said single-stranded DNA template; and wherein each of the oligonucleotides is either complementary to one contiguous DNA sequence stretch or to at least two non- contiguous DNA sequence stretches on said single-stranded DNA template. Also provided herein are associated methods, uses, compositions, and kits.

The application relates to the technical field of biological medicine, in particular to preparation and application of an anti-HPV6 virus L1 murine monoclonal antibody; the anti-HPV6 virus L1 murine monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the amino acid sequence of the heavy chain variable region is shown as SEQ ID No. 1; and the amino acid sequence of the light chain variable region is shown as SEQ ID No. 2. The murine monoclonal antibody is a unique single-chain antibody, and can be specifically combined with HPV6 virus L1. Western blot experiment results show that the HRP-labeled murine monoclonal antibody recombined in vitro is combined with HPV6 virus L1 to form obvious bands, and the murine monoclonal antibody has the characteristic of targeting HPV6 virus L1.

Described herein are fusion polypeptides comprising a sarbecovirus-binding moiety linked to a nanocage monomer or subunit thereof, wherein the sarbecovirus-binding moiety is capable of binding to SARS-CoV-2 and at least one sarbecovirus other than SARS-CoV-2. Methods for treating and / or preventing sarbecovirus infections and / or sarbecovirus-associated conditions are also described.

The present disclosure provides antibodies and antigen-binding fragments thereof that can bind to the S protein of Sabebe viruses (in some embodiments, including a plurality of Sabebe viruses) and, in certain embodiments, are capable of neutralizing infection by a plurality of Sabebe viruses.

The invention relates to the technical field of biological medicine, and discloses an anti-arenavirus NP protein monoclonal antibody, an anti-arenavirus NP protein single-chain antibody and a construction method and application of the anti-arenavirus NP protein single-chain antibody, the amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO: 1, and the amino acid sequence of a light chain variable region of the monoclonal antibody is shown as SEQ ID NO: 2. The invention provides a novel specific monoclonal antibody, the affinity of the monoclonal antibody to the arenavirus NP protein is strong, the monoclonal antibody can specifically recognize the NP protein and a new isolated strain, and the blank of an efficient antibody for the arenavirus NP protein with an unpublished sequence in the prior art is filled. Based on the sequence of the monoclonal antibody, the invention also designs a single-chain antibody, and the single-chain antibody has good stability and antigen (arenavirus) binding activity.